Article Sidebar
Published:
Sep 5, 2016DOI:
10.4314/tjpr.v15i8.4Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Inhibition of telomerase activity and cell growth by free and nanoliposomal forms of punicalagin in human leukemia cell line K562
Abstract
Purpose: To prepare punicalagin-loaded nanoliposome and compare its anti-telomerase activity in K562 cell line with that of free punicalagin.
Methods: Punicalagin-loaded nanoliposomes were prepared by extrusion method, and the efficiency of punicalagin entrapment was determined by high-performance liquid chromatography (HPLC) method. The anti-proliferation effect of the punicalagin in the free and nanoliposomal forms at various doses (0 - 100 μg/mL) and times (0 - 72 h) on K562 cell line was investigated using 3-(4,5 dimethylthiazol-2-yl)- 2,5-diphenyl tetrazolium bromide ((MTT) assay. Changes in telomerase activity, following treatment with punicalagin, of the free and nanoliposomal forms were measured by telomeric repeat amplification protocol-enzyme-linked immunosorbent assay.
Results: The entrapment efficiency of punicalagin was 86.7 ± 1 %. Treatment of K562 cells with punicalagin, particularly in the nanoliposomal form, resulted in significant induction of apoptosis and inhibition of cell growth. Furthermore, the telomerase activity of the nanoliposomal punicalagin-treated cells was significantly inhibited in a time- and dose-dependent manner.
Conclusion: Punicalagin shows a novel mechanism of anti-telomerase activity, particularly in the nanoliposomal form, and may provide a basis for the future development of anti-cancer therapy.
Keywords: Punicalagin, Apoptosis, Anti-proliferative, Nanoliposome, Telomerase, Leukemia
